Trevi Therapeutics (TRVI) to Release Quarterly Earnings on Tuesday

Trevi Therapeutics (NASDAQ:TRVI) is projected to issue its quarterly earnings data before the market opens on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Trevi Therapeutics Stock Up 7.3 %

Shares of Trevi Therapeutics stock opened at $6.75 on Monday. Trevi Therapeutics has a twelve month low of $2.30 and a twelve month high of $7.39. The stock has a market cap of $518.85 million, a price-to-earnings ratio of -15.34 and a beta of 0.90. The company’s fifty day moving average is $4.35 and its 200 day moving average is $3.63.

Insider Transactions at Trevi Therapeutics

In related news, insider Farrell Simon sold 81,313 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $6.75, for a total value of $548,862.75. Following the sale, the insider now owns 76,900 shares in the company, valued at $519,075. This represents a 51.39 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 24.37% of the company’s stock.

Analysts Set New Price Targets

TRVI has been the topic of several analyst reports. Needham & Company LLC boosted their price objective on shares of Trevi Therapeutics from $8.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday, March 10th. Oppenheimer upped their price target on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the company an “outperform” rating in a research report on Tuesday, March 11th. D. Boral Capital reaffirmed a “buy” rating and set a $21.00 price target on shares of Trevi Therapeutics in a research report on Friday, March 7th. HC Wainwright upped their price target on shares of Trevi Therapeutics from $7.50 to $12.50 and gave the company a “buy” rating in a research report on Monday, March 10th. Finally, Raymond James raised shares of Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and upped their price target for the company from $9.00 to $29.00 in a research report on Monday, March 10th. Seven research analysts have rated the stock with a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $15.94.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.